GlaxoSmithKline
GSK confirms job cuts but avoids specifics
February 5, 2010Research and Development, Sales and Marketing 2009 financials, GlaxoSmithKline
GlaxoSmithKline has sidestepped questions about the internal fall-out from its new plan to slash R&D infrastructure costs. Presenting the company’s …
GSK acquires respiratory candidate
February 4, 2010Research and Development Apeiron, GlaxoSmithKline, respiratory
GlaxoSmithKline has acquired exclusive rights to a biotherapeutic enzyme developed for use against Acute Respiratory Distress Syndrome (ARDS). The move …
Job cuts at GlaxoSmithKline and AstraZeneca
February 2, 2010Research and Development, Sales and Marketing AstraZeneca, GlaxoSmithKline
Britain’s two biggest pharma companies GlaxoSmithKline and AstraZeneca are poised to make deep job cuts as business models continue to …
Digital Pharma – Online patient recruitment drive for GSK’s anxiety drug
January 26, 2010Research and Development GlaxoSmithKline, PTSD, digital research, orvepitant, patient recruitment
GlaxoSmithKline is readying to move its post-traumatics stress disorder candidate orvepitant into phase II trials, a move being supported by …
GSK launches ‘Open Lab’ to share resources
January 21, 2010Research and Development, Sales and Marketing Africa, GlaxoSmithKline, malaria
GlaxoSmithKline has announced a series of measures to help improve medical treatment in poor countries. It has set up an …
Germany cuts GSK swine flu vaccine orders by 30%
January 13, 2010Sales and Marketing GlaxoSmithKline, Pandemrix, h1n1, swine flu
The Germany Ministry of Health has cut its order for GlaxoSmithKline’s swine flu vaccine Pandemrix by 30%. The pharma company …
Signs of product payoff from GSK’s $1.5bn alliance
January 12, 2010Research and Development ChemoCentryx, Crohn's, GlaxoSmithKline
GlaxoSmithKline is to develop and commercialise a drug which hopes will be a treatment for moderate-to-severe Crohn’s disease. Californian biotech …
GSK signs needle-free vaccine alliance
December 16, 2009Research and Development, Sales and Marketing GlaxoSmithKline, Intercell, patch, vaccines
GlaxoSmithKline has signed a deal with Intercell to see whether any of its vaccines could be made available in patch …
GSK begins phase III COPD trials
October 28, 2009Research and Development, Sales and Marketing COPD, GSK, GlaxoSmithKline, Seretide, Theravance, resp, respiratory
GlaxoSmithKline and San Francisco biopharma firm Theravance have begun a phase III trial to develop a new treatment for chronic …
GSK: Committed to improving UK clinical research
October 6, 2009Research and Development GSK, GlaxoSmithKline, NHS
GSK is the second biggest pharma company in the world, and Britain’s biggest homegrown firm in the sector. That means …
Pandemic planning: GSK’s Dr Neil Formica
September 1, 2009Research and Development GlaxoSmithKline, Vaccine, h1n1
The Pharmafocus interview: Simon Jose
February 20, 2009Sales and Marketing GlaxoSmithKline, Simon Jose, UK, partnerships, pricing
Like all his contemporaries in the UK, Simon Jose, GlaxoSmithKline’s head of UK operations has to focus on some of …
Groundbreaking pharma-NHS collaboration launched in Nottingham
May 30, 2008ABPI, ABPI Outreach Programme, AstraZeneca, Boehringer Ingelheim, COPD, GlaxoSmithKline, INFORCE, Nottingham, Nycomed, Pfizer, joint working
A group of pharmaceutical companies have joined forces with Nottingham healthcare services to help improve care for patients with chronic …
Arixtra approved for new blood clot indication
July 20, 2005Sales and Marketing Arixtra, GlaxoSmithKline
GlaxoSmithKline’s Arixtra has gained approval for use in preventing blood clots in high-risk patients undergoing abdominal surgery.The drug is already …
Latest content
